Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prenatal vitamin E and asthma

This article was originally published in The Tan Sheet

Executive Summary

Children are more likely to develop wheezing and asthma by age 5, if mothers do not have a sufficient intake of vitamin E during pregnancy, according to a study published in the September American Journal of Respiratory & Critical Care Medicine. The vitamin E levels and respiratory status of 1,253 mothers and children were assessed over a five-year period, Graham Devereux, MD, PhD, et al., Department of Environmental & Occupational Medicine, University of Aberdeen, UK, state. In a previous study, the researchers assessed vitamin E levels in 1,856 mothers at 12 weeks gestation and obtained symptom questionnaire data from 1,253 children. In light of the new findings, children born to mothers whose intakes of vitamin E ranked in the lowest quintile were five times more likely to manifest early persistent asthma than mothers with vitamin E intakes in the highest quintile, Devereux et al. state. The researchers suggest the relationship between prenatal vitamin E intake and children's rates of asthma "warrants further investigation," adding that vitamin E supplementation in adults who have asthma has not shown to provide clinical benefits...

You may also be interested in...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts